PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.\', \'Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA, USA.\', \'Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.\', \'Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA.\', \'Medicines for Malaria Venture, Geneva, Switzerland.\', \'Department of Microbiology, Thomas Jefferson University, Philadelphia, PA, USA. Electronic address: holly.ramage@jefferson.edu.\', \'Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: dschultz@upenn.edu.\', \'Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA, USA; Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: cherrys@pennmedicine.upenn.edu.\']
?:citedBy
  • -1
?:creator
?:doi
  • S2211-1247(21)00273-410.1016/j.celrep.2021.108959
?:doi
?:hasPublicationType
?:journal
  • Cell reports
is ?:pmid of
?:pmid
?:pmid
  • 33811811
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 7.552
?:rankingScore_hIndex
  • 92
is ?:relation_isRelatedTo_publication of
?:title
  • Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all